Quick Answer
Dogwood Therapeutics, Inc. reported Research And Development Expense of $21.87 million for the year ending 2025.
- Dogwood Therapeutics, Inc. showed an increase of +519.3% in Research And Development Expense from 2024 to 2025.
- This data is from Dogwood Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $30.5 thousand | Q2 2020: $23.3 thousand | Q3 2020: $108.1 thousand | Q1 2021: $1.71 million | Q2 2021: $3.21 million | Q3 2021: $2.96 million | Q1 2022: $2.77 million | Q2 2022: $2.41 million | Q3 2022: $1.62 million | Q1 2023: $497.7 thousand | Q2 2023: $557.8 thousand | Q3 2023: $374.2 thousand | Q1 2024: $343.7 thousand | Q2 2024: $336.1 thousand | Q3 2024: $535.2 thousand | Q1 2025: $2.44 million | Q2 2025: $2.57 million | Q3 2025: $14.52 million.
- Over the full 6 years of available data (2020 to 2025), Dogwood Therapeutics, Inc.'s Research And Development Expense has grown by 11,170.4%.
- Historical annual values: Fiscal year 2025: $21.87 million | Fiscal year 2024: $3.53 million | Fiscal year 2023: $1.73 million | Fiscal year 2022: $8.07 million | Fiscal year 2021: $10.80 million | Fiscal year 2020: $194.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: